永昕 (4726.TWO)

43.90 -0.60 (-1.35%) 市場開市。 截至 11:22AM CST。

永昕

No. 66, Shengyi 2nd Road
7th Floor
Zhubei 302041
Taiwan
886 3 667 0880
https://www.mycenax.com.tw

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Pei-Jiun Chen	President CEO & Chairman	7.61M	無	無
Mr. Chih-Yung Lin	Vice President	4.49M	無	無
Mr. Wei-I Chou	Associate Vice President of Pharmaceutical Development Division	3.45M	無	無
Mr. Chin-Hao Liang	Associate Vice President	2.73M	無	無
Ms. Yu-Ching Chang	Financial & Accounting Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

公司管治

截至 無 止，永昕 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。